VIR News and Press, Vir Biotechnology Inc. From 02/24/26

2026-02-24 14:15:03 ET Barclays analyst issues OVERWEIGHT recommendation for VIR on February 24, 2026 07:22PM ET. The previous analyst recommendation was Overweight. VIR was trading at $9.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-02-24 13:30:20 ET Investment Overview Vir Biotechnology, Inc. ( VIR ) stock is soaring today , up nearly 30% in early trading, reaching >$9.5 per share, which reflects a market cap valuation of $1.33bn.... Read the full article on Seeking Alpha For furthe...

DENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today’s developments are shaping a...

2026-02-24 08:15:06 ET Evercore ISI analyst issues OUTPERFORM recommendation for VIR on February 24, 2026 01:02PM ET. The previous analyst recommendation was Outperform. VIR was trading at $7.43 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2026-02-20 17:35:48 ET More on Vir Biotechnology Vir Biotechnology: The Low-Down On The Readouts Ahead Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morga...

2026-02-20 15:00:23 ET More on the markets VT: Still The Best Approach To Passive Investing U.S. GDP Set To Bounce Back After Government Shutdown Depresses Q4 Activity Why Static Portfolios Fail When Risk Regimes Change Trump says shutdown cut “at leas...

2026-02-17 07:04:10 ET from Barclays issued a price target of $26.00 for VIR on 2026-02-17 11:36:06. The adjusted price target was set to $26.00. At the time of the announcement, VIR was trading at $7.47. The overall price target consensus is at $19.50 with high price of...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be ...

2026-02-05 21:24:29 ET ... Read the full article on Seeking Alpha For further details see: Vir Biotechnology: The Low-Down On The Readouts Ahead

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Jan. 27, 2026 /CNW/ -- Equity-Insider.com   News Commentary – The global oncology therapy market is ...